For decades, oncology drug development has relied on the maximum tolerated dose (MTD) dose-finding method. With the United States Food and Drug Administration's (FDA's) Project Optimus initiative, the landscape of Phase I oncology trials is changing, and there is a greater focus on dose optimization and patient reported outcome.